Literature DB >> 35618341

Safety of SGLT2 Inhibitors in CKD: Walking the Fine Line.

Mirela Dobre1.   

Abstract

Entities:  

Keywords:  SGLT2; chronic kidney disease; sodium-glucose transporter 2 inhibitors

Mesh：

Substances：

Year:  2022        PMID： 35618341      PMCID： PMC9269644          DOI： 10.2215/CJN.04900422

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   10.614


× No keyword cloud information.
  7 in total

1.  KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2017-06-21

2.  Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study.

Authors:  Jenny E Blau; Viviana Bauman; Ellen M Conway; Paolo Piaggi; Mary F Walter; Elizabeth C Wright; Shanna Bernstein; Amber B Courville; Michael T Collins; Kristina I Rother; Simeon I Taylor
Journal:  JCI Insight       Date:  2018-04-19

3.  Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.

Authors:  Andrea Cowan; Nivethika Jeyakumar; Yuguang Kang; Stephanie N Dixon; Amit X Garg; Kyla Naylor; Matthew A Weir; Kristin K Clemens
Journal:  Clin J Am Soc Nephrol       Date:  2022-05-26       Impact factor: 10.614

4.  Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.

Authors:  Nelson B Watts; John P Bilezikian; Keith Usiskin; Robert Edwards; Mehul Desai; Gordon Law; Gary Meininger
Journal:  J Clin Endocrinol Metab       Date:  2015-11-18       Impact factor: 5.958

5.  Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.

Authors:  Jennifer R Donnan; Catherine A Grandy; Eugene Chibrikov; Carlo A Marra; Kris Aubrey-Bassler; Karissa Johnston; Michelle Swab; Jenna Hache; Daniel Curnew; Hai Nguyen; John-Michael Gamble
Journal:  BMJ Open       Date:  2019-02-01       Impact factor: 2.692

6.  Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.

Authors:  Min Zhuo; Chelsea E Hawley; Julie M Paik; Lily G Bessette; Deborah J Wexler; Dae H Kim; Angela Y Tong; Seoyoung C Kim; Elisabetta Patorno
Journal:  JAMA Netw Open       Date:  2021-10-01

7.  Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.

Authors:  Donald E Kohan; Paola Fioretto; Weihua Tang; James F List
Journal:  Kidney Int       Date:  2013-09-25       Impact factor: 10.612
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.